Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18673619 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | May 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18634259 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | April 2024 | March 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18583002 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18387420 | INHIBITORS OF MENIN-MLL INTERACTION | November 2023 | December 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18386224 | BICYCLIC AMINES AS CDK2 INHIBITORS | November 2023 | July 2025 | Allow | 20 | 1 | 1 | No | No |
| 18496692 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | October 2023 | July 2024 | Allow | 9 | 0 | 0 | No | No |
| 18487159 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | October 2023 | December 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18467162 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18243068 | PYRROLO[2,3-C][1,6]NAPHTHYRIDINE-8-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 1 | Yes | No |
| 18241350 | 5-SUBSTITUTED PYRIDO[3'',4'':4',5']PYRROLO[3',2':4,5]IMIDAZO[1,2-a]PYRAZINE COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18365286 | PROTEIN KINASE B INHIBITORS | August 2023 | November 2024 | Allow | 15 | 1 | 1 | No | No |
| 18363600 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | August 2023 | May 2024 | Allow | 10 | 1 | 1 | No | No |
| 18351752 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | July 2023 | May 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18347345 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | July 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18214327 | LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERS | June 2023 | November 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18196002 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | May 2023 | December 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18143720 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18124827 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | March 2023 | March 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18185227 | PYRAZOLE MAGL INHIBITORS | March 2023 | December 2024 | Allow | 21 | 1 | 0 | No | No |
| 18176389 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | February 2023 | November 2024 | Abandon | 20 | 0 | 0 | Yes | No |
| 18112699 | PROCESS FOR THE PREPARATION OF SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B] [1,3] OXAZEPIN-8-OLATE AND ITS POLYMORPHIC FORM | February 2023 | May 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18041731 | THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USE | February 2023 | August 2024 | Allow | 18 | 4 | 1 | Yes | No |
| 18166008 | BETULASTATIN COMPOUNDS | February 2023 | November 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18101009 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | January 2023 | June 2024 | Allow | 16 | 0 | 1 | No | No |
| 18157783 | METHODS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS | January 2023 | September 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18096392 | FUSED HETEROAROMATIC PYRROLIDINONES | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18086397 | Derivative of berberine, and the preparation method and application thereof | December 2022 | November 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 18069646 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | December 2022 | March 2024 | Allow | 15 | 0 | 0 | No | No |
| 18083602 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | December 2022 | March 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18084208 | MORPHOLINYLPYRIDONE COMPOUNDS | December 2022 | July 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18074889 | GLUCAGON RECEPTOR ANTAGONIST AND USE THEREOF | December 2022 | June 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 17924792 | CRYSTALLINE SALT OF ERIBULIN | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17997983 | FREE BASE CRYSTALS | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18050650 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | October 2022 | August 2024 | Allow | 22 | 2 | 1 | No | No |
| 18049344 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | October 2022 | July 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17967483 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | October 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17967508 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | October 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17952460 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | September 2022 | May 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17933850 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | September 2022 | January 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17932876 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | September 2022 | July 2023 | Allow | 10 | 1 | 1 | No | No |
| 17901007 | DOPAMINE-B-HYDROXYLASE INHIBITORS | September 2022 | December 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17823254 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | August 2022 | June 2025 | Allow | 34 | 3 | 1 | No | Yes |
| 17891869 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | August 2022 | July 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17887325 | MATERIAL FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS | August 2022 | December 2022 | Allow | 4 | 1 | 1 | Yes | No |
| 17818873 | STEROIDS AND METHODS OF MANUFACTURE | August 2022 | March 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 17878495 | ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS | August 2022 | May 2023 | Allow | 9 | 0 | 1 | Yes | No |
| 17874324 | Novel compounds and their use in therapy | July 2022 | January 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17873248 | NEAR-INFRARED FLUORESCENT INDICATORS FOR LYSOSOME AND APPLICATION THEREOF | July 2022 | December 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17870885 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | July 2022 | December 2024 | Allow | 29 | 4 | 1 | Yes | No |
| 17870156 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | July 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17814224 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | July 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17870151 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | July 2022 | December 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17813805 | TYK2 INHIBITORS AND USES THEREOF | July 2022 | April 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17864106 | MAP4K1 INHIBITORS | July 2022 | June 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17810915 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | July 2022 | May 2025 | Allow | 35 | 3 | 1 | No | Yes |
| 17855672 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | June 2022 | October 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17790042 | PROCESS FOR THE SYNTHESIS OF BUPRENORPHINE | June 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17853647 | AhR MODULATORS | June 2022 | November 2024 | Allow | 29 | 3 | 1 | No | No |
| 17850668 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | June 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17831760 | (17-)-3-Oxoandrost-4-EN-17-YL Dodecanoate Compositions and Methods of Preparation and Use | June 2022 | May 2025 | Allow | 35 | 4 | 1 | Yes | Yes |
| 17781095 | METHOD FOR SYNTHESIZING URSODEOXYCHOLIC ACID USING BA AS RAW MATERIAL | May 2022 | June 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17804012 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | May 2022 | July 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17748470 | TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17746446 | BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS | May 2022 | October 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17663551 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | May 2022 | June 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17660355 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17655293 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | March 2022 | August 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17694757 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | March 2022 | October 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17689510 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | March 2022 | March 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17687826 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | March 2022 | March 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17640506 | SIDEROPHORE CEPHALOSPORIN CONJUGATES AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17652076 | LUMATEPERONE BIS-TOSYLATE SALTS AND CRYSTALS AND METHODS FOR MANUFACTURE THEREOF | February 2022 | September 2024 | Allow | 31 | 2 | 1 | Yes | Yes |
| 17674943 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | February 2022 | January 2024 | Allow | 23 | 2 | 1 | No | No |
| 17417613 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | February 2022 | June 2023 | Allow | 23 | 0 | 0 | Yes | No |
| 17635928 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | February 2022 | January 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17636014 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | February 2022 | January 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17650155 | P2X7 MODULATORS | February 2022 | February 2025 | Allow | 36 | 4 | 1 | No | Yes |
| 17648045 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | January 2022 | January 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17574132 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | January 2022 | November 2023 | Allow | 22 | 3 | 1 | Yes | No |
| 17625494 | METASTABLE CRYSTAL MODIFICATION AND METHOD FOR PRODUCING THE SAME (I) | January 2022 | July 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17623252 | REFINING METHOD OF MIDBODY OF LATAMOXEF SODIUM | December 2021 | April 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17623041 | IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OF | December 2021 | December 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17557174 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | December 2021 | June 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17621023 | PROCESS FOR THE PREPARATION OF A METASTABLE CRYSTAL MODIFICATION OF N-(AMINOIMINOMETHYL)-2-AMINOACETIC ACID (III) | December 2021 | December 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17620410 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17620239 | EGFR INHIBITOR FOR THE TREATMENT OF CANCER | December 2021 | April 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17644654 | PROTEIN KINASE B INHIBITORS | December 2021 | July 2023 | Allow | 19 | 1 | 1 | No | No |
| 17596674 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17617851 | CGRP ANTAGONIST COMPOUNDS | December 2021 | October 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17546133 | SOLID FORMS OF 2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDIN-2-YL)-N-BENZYLACETAMIDE | December 2021 | September 2024 | Allow | 34 | 2 | 1 | No | No |
| 17536925 | Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile | November 2021 | May 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17595651 | CRYSTAL FORM OF PYRIMIDINE SULFONAMIDE COMPOUND AND PREPARATION METHOD THEREFOR | November 2021 | September 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17455507 | FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAME | November 2021 | March 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17519590 | SYNTHESIS OF ERIBULIN MESYLATE | November 2021 | April 2023 | Allow | 18 | 0 | 0 | No | No |
| 17604194 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | October 2021 | March 2025 | Allow | 41 | 2 | 0 | No | No |
| 17499230 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | October 2021 | May 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17601390 | METHODS OF TREATING NEUROPATHIC PAIN | October 2021 | June 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17449779 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | October 2021 | October 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17488317 | Preparation and Application of A 5-bromoquinazoline Derivative | September 2021 | August 2023 | Allow | 23 | 2 | 0 | No | No |
| 17441788 | TYK2 PSEUDOKINASE LIGANDS | September 2021 | May 2023 | Allow | 20 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOORE, SUSANNA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOORE, SUSANNA works in Art Unit 1624 and has examined 1,574 patent applications in our dataset. With an allowance rate of 66.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner MOORE, SUSANNA's allowance rate of 66.8% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOORE, SUSANNA receive 1.62 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MOORE, SUSANNA is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +41.9% benefit to allowance rate for applications examined by MOORE, SUSANNA. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 61.0% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 89.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.9% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.